These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

377 related items for PubMed ID: 21942463

  • 1. Comparative effectiveness of budesonide/formoterol and fluticasone/salmeterol for COPD management.
    Roberts M, Mapel D, Petersen H, Blanchette C, Ramachandran S.
    J Med Econ; 2011; 14(6):769-76. PubMed ID: 21942463
    [Abstract] [Full Text] [Related]

  • 2. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence.
    Blais L, Forget A, Ramachandran S.
    Clin Ther; 2010 Jul; 32(7):1320-8. PubMed ID: 20678680
    [Abstract] [Full Text] [Related]

  • 3. Comparative effectiveness of budesonide/formoterol combination and fluticasone/salmeterol combination among chronic obstructive pulmonary disease patients new to controller treatment: a US administrative claims database study.
    Kern DM, Davis J, Williams SA, Tunceli O, Wu B, Hollis S, Strange C, Trudo F.
    Respir Res; 2015 Apr 23; 16(1):52. PubMed ID: 25899176
    [Abstract] [Full Text] [Related]

  • 4. Comparative effectiveness of budesonide-formoterol combination and fluticasone-salmeterol combination for asthma management: a United States retrospective database analysis.
    Tunceli O, Williams SA, Kern DM, Elhefni H, Pethick N, Wessman C, Zhou S, Trudo F.
    J Allergy Clin Immunol Pract; 2014 Apr 23; 2(6):719-26. PubMed ID: 25439363
    [Abstract] [Full Text] [Related]

  • 5. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
    Blanchette CM, Akazawa M, Dalal A, Simoni-Wastila L.
    Am J Geriatr Pharmacother; 2008 Aug 23; 6(3):138-46. PubMed ID: 18775388
    [Abstract] [Full Text] [Related]

  • 6. Health Care Utilization and Costs After Initiating Budesonide/Formoterol Combination or Fluticasone/Salmeterol Combination Among COPD Patients New to ICS/LABA Treatment.
    Davis JR, Kern DM, Williams SA, Tunceli O, Wu B, Hollis S, Strange C, Trudo F.
    J Manag Care Spec Pharm; 2016 Mar 23; 22(3):293-304. PubMed ID: 27003559
    [Abstract] [Full Text] [Related]

  • 7. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study.
    Larsson K, Janson C, Lisspers K, Jørgensen L, Stratelis G, Telg G, Ställberg B, Johansson G.
    J Intern Med; 2013 Jun 23; 273(6):584-94. PubMed ID: 23495860
    [Abstract] [Full Text] [Related]

  • 8. Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen.
    Rascati KL, Akazawa M, Johnsrud M, Stanford RH, Blanchette CM.
    Clin Ther; 2007 Jun 23; 29(6):1203-13. PubMed ID: 17692734
    [Abstract] [Full Text] [Related]

  • 9. Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease.
    Dalal AA, Roberts MH, Petersen HV, Blanchette CM, Mapel DW.
    Int J Chron Obstruct Pulmon Dis; 2010 Dec 31; 6():13-22. PubMed ID: 21311689
    [Abstract] [Full Text] [Related]

  • 10. Comparative effectiveness of budesonide/formoterol combination and tiotropium bromide among COPD patients new to these controller treatments.
    Trudo F, Kern DM, Davis JR, Tunceli O, Zhou S, Graham EL, Strange C, Williams SA.
    Int J Chron Obstruct Pulmon Dis; 2015 Dec 31; 10():2055-66. PubMed ID: 26451101
    [Abstract] [Full Text] [Related]

  • 11. Effects of fluticasone propionate/salmeterol combination on asthma-related health care resource utilization and costs and adherence in children and adults with asthma.
    Delea TE, Hagiwara M, Stanford RH, Stempel DA.
    Clin Ther; 2008 Mar 31; 30(3):560-71. PubMed ID: 18405796
    [Abstract] [Full Text] [Related]

  • 12. Rehospitalization risks and outcomes in COPD patients receiving maintenance pharmacotherapy.
    Dalal AA, Shah M, D'Souza AO, Crater GD.
    Respir Med; 2012 Jun 31; 106(6):829-37. PubMed ID: 22425138
    [Abstract] [Full Text] [Related]

  • 13. Acute care among asthma patients using budesonide/formoterol or fluticasone propionate/salmeterol.
    Blais L, Beauchesne MF, Forget A.
    Respir Med; 2009 Feb 31; 103(2):237-43. PubMed ID: 18930647
    [Abstract] [Full Text] [Related]

  • 14. Budesonide/formoterol as maintenance and reliever treatment compared to fixed dose combination strategies - a Canadian economic evaluation.
    Miller E, FitzGerald JM.
    Can J Clin Pharmacol; 2008 Feb 31; 15(2):e165-76. PubMed ID: 18515918
    [Abstract] [Full Text] [Related]

  • 15. Association between previous health care use and initiation of inhaled corticosteroid and long-acting beta2-adrenergic agonist combination therapy among US patients with asthma.
    Blanchette CM, Culler SD, Ershoff D, Gutierrez B.
    Clin Ther; 2009 Nov 31; 31(11):2574-83. PubMed ID: 20110003
    [Abstract] [Full Text] [Related]

  • 16. Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma.
    Johansson G, Andreasson EB, Larsson PE, Vogelmeier CF.
    Pharmacoeconomics; 2006 Nov 31; 24(7):695-708. PubMed ID: 16802845
    [Abstract] [Full Text] [Related]

  • 17. The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma.
    FitzGerald JM, Boulet LP, Follows RM.
    Clin Ther; 2005 Apr 31; 27(4):393-406. PubMed ID: 15922813
    [Abstract] [Full Text] [Related]

  • 18. A US database study characterizing patients initiating a budesonide-formoterol combination versus tiotropium bromide as initial maintenance therapy for chronic obstructive pulmonary disease.
    Kern DM, Williams SA, Tunceli O, Wessman C, Zhou S, Pethick N, Elhefni H, Trudo F.
    Int J Chron Obstruct Pulmon Dis; 2014 Apr 31; 9():775-83. PubMed ID: 25071369
    [Abstract] [Full Text] [Related]

  • 19. Impact of adherence to treatment with tiotropium and fluticasone propionate/salmeterol in chronic obstructive pulmonary diseases patients.
    Ismaila A, Corriveau D, Vaillancourt J, Parsons D, Dalal A, Su Z, Sampalis JS.
    Curr Med Res Opin; 2014 Jul 31; 30(7):1427-36. PubMed ID: 24666181
    [Abstract] [Full Text] [Related]

  • 20. Economic assessment of initial maintenance therapy for chronic obstructive pulmonary disease.
    Akazawa M, Hayflinger DC, Stanford RH, Blanchette CM.
    Am J Manag Care; 2008 Jul 31; 14(7):438-48. PubMed ID: 18611095
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.